Fisher A, Brandeis R, Pittel Z, Haring R, Sparks L, Beach TG, Bons N, Maestre-Frances N, Bar-Ner N, Kliger-Spatz M, Natan N, Marcovitch I, Hartmann T (2004) <br />Poster (46) Major hallmarks in alzheimer's disease (ad) can beneficially be modulated by M1 muscarinic agonists - an added value vs. cholinesterase inhibitors<br /><i>In: Cholinesterases in the Second Millennium: Biomolecular and Pathological Aspects</i> <b> (Inestrosa NC, Campos EO) P. Universidad Catolica de Chile-FONDAP Biomedicina</b>: 345<br /><br />Pittel Z, Haring R, Bons N, Bar-Ner N, Sonego H, Natan N, Marcovitch I, Brandeis R (2004) <br />Beta-amyloids, tau hyperphosphorylation and cognition are beneficially affected by M1 muscarinic agonists.<br /><i>Cholinergic Mechanisms, CRC Press</i> <br /><br />Fisher A, Pittel Z, Haring R, Bar-Ner N, Kliger-Spatz M, Natan N, Egozi I, Sonego H, Marcovitch I, Brandeis R (2003) <br />M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy<br /><i>Journal of Molecular Neuroscience</i> <b>20</b>: 349<br /><br />Fisher A, Michaelson DM, Brandeis R, Haring R, Chapman S, Pittel Z (2000) <br />M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectives<br /><i>Annals of the New York Academy of Sciences</i> <b>920</b>: 315<br /><br />Pittel Z, Fisher A, Eshhar N, Haring R, Heldman E (1999) <br />Poster: Effect of muscarinic stimulation on beta-amyloid precursor protein processing in rat brain and primary cultures<br /><i>Life Sciences</i> <b>64</b>: 572<br /><br />Fisher A, Brandeis R, Haring R, Eshhar N, Heldman E, Karton Y, Eisenberg O, Meshulam H, Marciano D, Bar-Ner N, Pittel Z (1998) <br />Novel m1 muscarinic agonists in treatment and delaying the progression of Alzheimer's disease: An unifying hypothesis<br /><i>Journal de Physiologie (Paris)</i> <b>92</b>: 337<br /><br />Haring R, Eshhar N, Heldman E, Marciano D, Kloog Y, Fisher A (1997) <br />Poster: An M1 selective agonist AF102b, as a potential drug in treatment of Alzheimer's disease: Biochemical and pharmacological properties<br /><i>Life Sciences</i> <b>60</b>: 1183<br /><br />Danenberg HD, Haring R, Fisher A, Pittel Z, Gurwitz D, Heldman E (1996) <br />Dehydroepiandrosterone (DHEA) increases production and release of Alzheimer's amyloid precursor protein<br /><i>Life Sciences</i> <b>59</b>: 1651<br /><br />Fisher A, Heldman E, Gurwitz D, Haring R, Karton Y, Meshulam H, Pittel Z, Marciano D, Brandeis R, Sadot E, Barg Y, Pinkas-Kramarski R, Vogel Z, Ginzburg I, Treves TA, Verchovsky R, Klimowsky S, Korczyn AD (1996) <br />M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update<br /><i>Annals of the New York Academy of Sciences</i> <b>777</b>: 189<br /><br />Pittel Z, Heldman E, Barg J, Haring R, Fisher A (1996) <br />Muscarinic control of amyloid precursor protein secretion in rat cerebral cortex and cerebellum<br /><i>Brain Research</i> <b>742</b>: 299<br /><br />Danenberg HD, Haring R, Heldman E, Gurwitz D, Ben-Nathan D, Pittel Z, Zuckerman A, Fisher A (1995) <br />Dehydroepiandrosterone augments M1-muscarinic receptor-stimulated amyloid precursor protein secretion in desensitized PC12M1 cells<br /><i>Annals of the New York Academy of Sciences</i> <b>774</b>: 300<br /><br />Gurwitz D, Haring R, Heldman E, Fraser CM, Manor D, Fisher A (1994) <br />Discrete activation of transduction pathways associated with acetylcholine m1 receptor by several muscarinic ligands<br /><i>European Journal of Pharmacology</i> <b>267</b>: 21<br /><br />Fisher A, Heldman E, Gurwitz D, Haring R, Barak D, Meshulam H, Marciano D, Brandeis R, Pittel Z, Segal M, et al. (1993) <br />Selective signaling via unique M1 muscarinic agonists<br /><i>Annals of the New York Academy of Sciences</i> <b>695</b>: 300<br /><br />Fisher A, Karton Y, Heldman E, Gurwitz D, Haring R, Meshulam H, Brandeis R, Pittel Z, Segall Y, Marciano D, et al. (1993) <br />Progress in medicinal chemistry of novel selective muscarinic agonists<br /><i>Drug Des Discov</i> <b>9</b>: 221<br /><br />Fisher A, Brandeis R, Karton I, Pittel Z, Gurwitz D, Haring R, Sapir M, Levy A, Heldman E (1991) <br />(+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3')quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's disease<br /><i>Journal of Pharmacology & Experimental Therapeutics</i> <b>257</b>: 392<br /><br />Mosckovitz R, Haring R, Gershoni JM, Kloog Y, Sokolovsky M (1987) <br />Localization of azidophencyclidine-binding site on the nicotinic acetylcholine receptor alpha-subunit<br /><i>Biochemical & Biophysical Research Communications</i> <b>145</b>: 810<br /><br />